Serving the IO and Cell Therapy Community

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

Engineering advancements in T cell manufacturing can lead to reduced associated production costs for CAR T cell therapies, enabling broader access and scalability for patient benefit.

July 25, 2025

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

Summary:

Accessibility to CAR-T is limited by traditional manufacturing, with its associated challenges and high cost. Moffitt Cancer Center's Chief BioEngineering Officer, Dr Greg Sawyer, highlights Moffitt's progress in enhancing T cell potency and boosting efficacy through engineering strategies. Dr Sawyer also discusses assays enabling precise assessment of T cell potency and developments in manufacturing, and the resulting impact on scalability and efficiency.

This presentation comes from the March 2025 Immuno-Oncology 360º Summit. For more information, go to IO360summit.com.

In this podcast